Cargando…

Human factors evaluation of a novel digital medicine system in psychiatry

BACKGROUND: The digital medicine system (DMS), a drug–device combination developed for patients with serious mental illness, integrates adherence measurement with pharmacologic treatment by embedding an ingestible sensor in a pill, allowing for information sharing among patients, health care provide...

Descripción completa

Detalles Bibliográficos
Autores principales: Peters-Strickland, Timothy, Hatch, Ainslie, Adenwala, Anke, Atkinson, Katie, Bartfeld, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818865/
https://www.ncbi.nlm.nih.gov/pubmed/29497299
http://dx.doi.org/10.2147/NDT.S157102
_version_ 1783301096402321408
author Peters-Strickland, Timothy
Hatch, Ainslie
Adenwala, Anke
Atkinson, Katie
Bartfeld, Benjamin
author_facet Peters-Strickland, Timothy
Hatch, Ainslie
Adenwala, Anke
Atkinson, Katie
Bartfeld, Benjamin
author_sort Peters-Strickland, Timothy
collection PubMed
description BACKGROUND: The digital medicine system (DMS), a drug–device combination developed for patients with serious mental illness, integrates adherence measurement with pharmacologic treatment by embedding an ingestible sensor in a pill, allowing for information sharing among patients, health care providers (HCPs), and caregivers via a mobile interface. Studies conducted during the DMS development process aimed to minimize cognitive burden and use-related risks and demonstrated effective use of the technology. METHODS: Human factors (HF) studies assessed the system’s safe and effective use by the intended users for the intended uses. The patient interface was tested in six formative HF studies followed by a validation study. The HCP/caregiver interface was tested in one study before validation. All tasks critical to safety or necessary for effective use were included. Formative studies identified use-related risks and the causes of use problems to guide design modification. Validation of the patient and HCP/caregiver interfaces assessed risks of the final product. RESULTS: During the patient formative studies, design improvements were made to address problems and mitigate risks thought to be associated with a suboptimal system design or patient understanding of the system. In the validation study of the patient interface, 35 patients attempted 23 performance tasks, for a total of 805 attempts; 783/805 attempts were completed with success. One close call, 15 failures, and 6 difficulties occurred on these user tasks; only 3 of these were on a critical task. Residual risks resistant to mitigation were found to be of low severity based on the US Food and Drug Administration 2016 guidance. CONCLUSION: The final design of the DMS reflects input by the intended user populations through a comprehensive development methodology. In alignment with the US Food and Drug Administration goals for HF studies, the system was found to be safe and effective for the intended users, uses, and use environments.
format Online
Article
Text
id pubmed-5818865
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-58188652018-03-01 Human factors evaluation of a novel digital medicine system in psychiatry Peters-Strickland, Timothy Hatch, Ainslie Adenwala, Anke Atkinson, Katie Bartfeld, Benjamin Neuropsychiatr Dis Treat Original Research BACKGROUND: The digital medicine system (DMS), a drug–device combination developed for patients with serious mental illness, integrates adherence measurement with pharmacologic treatment by embedding an ingestible sensor in a pill, allowing for information sharing among patients, health care providers (HCPs), and caregivers via a mobile interface. Studies conducted during the DMS development process aimed to minimize cognitive burden and use-related risks and demonstrated effective use of the technology. METHODS: Human factors (HF) studies assessed the system’s safe and effective use by the intended users for the intended uses. The patient interface was tested in six formative HF studies followed by a validation study. The HCP/caregiver interface was tested in one study before validation. All tasks critical to safety or necessary for effective use were included. Formative studies identified use-related risks and the causes of use problems to guide design modification. Validation of the patient and HCP/caregiver interfaces assessed risks of the final product. RESULTS: During the patient formative studies, design improvements were made to address problems and mitigate risks thought to be associated with a suboptimal system design or patient understanding of the system. In the validation study of the patient interface, 35 patients attempted 23 performance tasks, for a total of 805 attempts; 783/805 attempts were completed with success. One close call, 15 failures, and 6 difficulties occurred on these user tasks; only 3 of these were on a critical task. Residual risks resistant to mitigation were found to be of low severity based on the US Food and Drug Administration 2016 guidance. CONCLUSION: The final design of the DMS reflects input by the intended user populations through a comprehensive development methodology. In alignment with the US Food and Drug Administration goals for HF studies, the system was found to be safe and effective for the intended users, uses, and use environments. Dove Medical Press 2018-02-16 /pmc/articles/PMC5818865/ /pubmed/29497299 http://dx.doi.org/10.2147/NDT.S157102 Text en © 2018 Peters-Strickland et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Peters-Strickland, Timothy
Hatch, Ainslie
Adenwala, Anke
Atkinson, Katie
Bartfeld, Benjamin
Human factors evaluation of a novel digital medicine system in psychiatry
title Human factors evaluation of a novel digital medicine system in psychiatry
title_full Human factors evaluation of a novel digital medicine system in psychiatry
title_fullStr Human factors evaluation of a novel digital medicine system in psychiatry
title_full_unstemmed Human factors evaluation of a novel digital medicine system in psychiatry
title_short Human factors evaluation of a novel digital medicine system in psychiatry
title_sort human factors evaluation of a novel digital medicine system in psychiatry
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818865/
https://www.ncbi.nlm.nih.gov/pubmed/29497299
http://dx.doi.org/10.2147/NDT.S157102
work_keys_str_mv AT petersstricklandtimothy humanfactorsevaluationofanoveldigitalmedicinesysteminpsychiatry
AT hatchainslie humanfactorsevaluationofanoveldigitalmedicinesysteminpsychiatry
AT adenwalaanke humanfactorsevaluationofanoveldigitalmedicinesysteminpsychiatry
AT atkinsonkatie humanfactorsevaluationofanoveldigitalmedicinesysteminpsychiatry
AT bartfeldbenjamin humanfactorsevaluationofanoveldigitalmedicinesysteminpsychiatry